1279 related articles for article (PubMed ID: 32966331)
1. Familial Alzheimer's disease mutations at position 22 of the amyloid β-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system.
Tackenberg C; Kulic L; Nitsch RM
PLoS One; 2020; 15(9):e0239584. PubMed ID: 32966331
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease amyloid β-protein mutations and deletions that define neuronal binding/internalization as early stage nonfibrillar/fibrillar aggregates and late stage fibrils.
Poduslo JF; Howell KG; Olson NC; Ramirez-Alvarado M; Kandimalla KK
Biochemistry; 2012 May; 51(19):3993-4003. PubMed ID: 22545812
[TBL] [Abstract][Full Text] [Related]
3. Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Aβ APP mutation.
Kulic L; McAfoose J; Welt T; Tackenberg C; Späni C; Wirth F; Finder V; Konietzko U; Giese M; Eckert A; Noriaki K; Shimizu T; Murakami K; Irie K; Rasool S; Glabe C; Hock C; Nitsch RM
Transl Psychiatry; 2012 Nov; 2(11):e183. PubMed ID: 23149447
[TBL] [Abstract][Full Text] [Related]
4. Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tau.
Tackenberg C; Brandt R
J Neurosci; 2009 Nov; 29(46):14439-50. PubMed ID: 19923278
[TBL] [Abstract][Full Text] [Related]
5. The Osaka FAD mutation E22Δ leads to the formation of a previously unknown type of amyloid β fibrils and modulates Aβ neurotoxicity.
Ovchinnikova OY; Finder VH; Vodopivec I; Nitsch RM; Glockshuber R
J Mol Biol; 2011 May; 408(4):780-91. PubMed ID: 21402079
[TBL] [Abstract][Full Text] [Related]
6. Co-occurrence of Alzheimer's disease ß-amyloid and τ pathologies at synapses.
Takahashi RH; Capetillo-Zarate E; Lin MT; Milner TA; Gouras GK
Neurobiol Aging; 2010 Jul; 31(7):1145-52. PubMed ID: 18771816
[TBL] [Abstract][Full Text] [Related]
7. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.
Nussbaum JM; Schilling S; Cynis H; Silva A; Swanson E; Wangsanut T; Tayler K; Wiltgen B; Hatami A; Rönicke R; Reymann K; Hutter-Paier B; Alexandru A; Jagla W; Graubner S; Glabe CG; Demuth HU; Bloom GS
Nature; 2012 May; 485(7400):651-5. PubMed ID: 22660329
[TBL] [Abstract][Full Text] [Related]
8. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.
Zago W; Buttini M; Comery TA; Nishioka C; Gardai SJ; Seubert P; Games D; Bard F; Schenk D; Kinney GG
J Neurosci; 2012 Feb; 32(8):2696-702. PubMed ID: 22357853
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
11. Modeling Alzheimer's disease in mouse without mutant protein overexpression: cooperative and independent effects of Aβ and tau.
Guo Q; Li H; Cole AL; Hur JY; Li Y; Zheng H
PLoS One; 2013; 8(11):e80706. PubMed ID: 24278307
[TBL] [Abstract][Full Text] [Related]
12. On the role of sidechain size and charge in the aggregation of A
Yang X; Meisl G; Frohm B; Thulin E; Knowles TPJ; Linse S
Proc Natl Acad Sci U S A; 2018 Jun; 115(26):E5849-E5858. PubMed ID: 29895690
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer's disease.
Chabrier MA; Cheng D; Castello NA; Green KN; LaFerla FM
Neurobiol Dis; 2014 Apr; 64():107-17. PubMed ID: 24440055
[TBL] [Abstract][Full Text] [Related]
14. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
[TBL] [Abstract][Full Text] [Related]
15. Wnt signaling loss accelerates the appearance of neuropathological hallmarks of Alzheimer's disease in J20-APP transgenic and wild-type mice.
Tapia-Rojas C; Inestrosa NC
J Neurochem; 2018 Feb; 144(4):443-465. PubMed ID: 29240990
[TBL] [Abstract][Full Text] [Related]
16. The type of Aβ-related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid β-peptide (APP48) transgenic mice.
Rijal Upadhaya A; Scheibe F; Kosterin I; Abramowski D; Gerth J; Kumar S; Liebau S; Yamaguchi H; Walter J; Staufenbiel M; Thal DR
Acta Neuropathol Commun; 2013 Nov; 1(1):77. PubMed ID: 24252227
[TBL] [Abstract][Full Text] [Related]
17. NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss.
Tackenberg C; Grinschgl S; Trutzel A; Santuccione AC; Frey MC; Konietzko U; Grimm J; Brandt R; Nitsch RM
Cell Death Dis; 2013 Apr; 4(4):e608. PubMed ID: 23618906
[TBL] [Abstract][Full Text] [Related]
18. Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease.
Saul A; Sprenger F; Bayer TA; Wirths O
Neurobiol Aging; 2013 Nov; 34(11):2564-73. PubMed ID: 23747045
[TBL] [Abstract][Full Text] [Related]
19. The structures of the E22Δ mutant-type amyloid-β alloforms and the impact of E22Δ mutation on the structures of the wild-type amyloid-β alloforms.
Coskuner O; Wise-Scira O; Perry G; Kitahara T
ACS Chem Neurosci; 2013 Feb; 4(2):310-20. PubMed ID: 23421682
[TBL] [Abstract][Full Text] [Related]
20. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
